IHU RespirERA continues its commitment to scientific innovation with the acquisition of the AVITI24 platform, developed by Element Biosciences. This latest-generation equipment strengthens the institute’s research capabilities to better understand the mechanisms underlying respiratory diseases and to develop new therapeutic approaches.
Much more than a simple genetic sequencer (a device used to read the information contained in DNA or RNA), AVITI24 is a technological platform capable of simultaneously analysing several dimensions of cellular function. Through this so-called multiomics approach, researchers can study within a single experiment gene expression (RNA), the presence of proteins, and the internal organisation of cells. This comprehensive view makes it possible to better understand how respiratory cells function, how they evolve during disease, and how they respond to treatment.
Another major advance is that the platform enables analysis at the single-cell level, meaning that each cell can be studied individually rather than as part of a mixed population. AVITI24 can analyse up to 2 million cells in a single analysis cycle, offering unprecedented precision for identifying biomarkers, deciphering the biological mechanisms involved in diseases such as asthma, pulmonary fibrosis, or COPD (chronic obstructive pulmonary disease), and supporting the development of precision medicine strategies.
Thanks to its innovative technologies and the high quality of the data it generates, AVITI24 will also accelerate research into the effectiveness of new therapeutic molecules. Researchers will be able to observe more precisely how treatments affect cells and better understand the mechanisms of action of medications.
With this investment, IHU RespirERA strengthens its technological ecosystem and its ability to collaborate with international research teams. The objective is clear: to translate scientific discoveries more rapidly into concrete advances that improve the care of patients living with respiratory diseases.
